Teva Pharma (TEVA)
30.15
-1.20 (3.83%)
Upcoming Events
Latest Headlines
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
July 20, 2026 8:40 AM - StreetInsider
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
July 20, 2026 8:38 AM - StreetInsider
Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 17, 2026 4:29 PM - SEC Filing
Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew
July 16, 2026 4:11 PM - SEC Filing
Teva lawsuit against Eli Lilly over Forteo revived by appeals court
July 13, 2026 3:27 PM - StreetInsider
Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
July 7, 2026 7:36 AM - StreetInsider
UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
June 26, 2026 9:35 AM - StreetInsider
Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.
June 24, 2026 4:11 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew
June 22, 2026 4:01 PM - SEC Filing
Teva submits NDA for ecopipam to treat pediatric Tourette syndrome
June 18, 2026 4:58 PM - StreetInsider
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
June 18, 2026 4:56 PM - Globe NewsWire
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Shields Matthew
June 18, 2026 4:15 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 15 Filed by: Hall Brett Matthew
June 16, 2026 4:15 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 11 Filed by: Kalif Eliyahu Sharon
June 16, 2026 8:28 AM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 15, 2026 4:12 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Schall Thomas J.
June 11, 2026 5:38 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: HAUSMAN DIANA
June 11, 2026 5:33 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: CARPENTER ROBERT J
June 11, 2026 5:30 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: KEATING LAURIE
June 11, 2026 5:26 PM - SEC Filing
Form 4 Immuneering Corp For: Jun 11 Filed by: Feinberg Peter
June 11, 2026 5:23 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 11
June 11, 2026 5:16 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Kalif Eliyahu Sharon
June 11, 2026 4:01 PM - SEC Filing
Immuneering doses first patient in phase 3 pancreatic cancer trial
June 11, 2026 7:30 AM - StreetInsider
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
June 11, 2026 7:30 AM - Globe NewsWire
Teva completes $700 million acquisition of Emalex Biosciences
June 10, 2026 12:03 PM - StreetInsider
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 10, 2026 12:03 PM - Globe NewsWire
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: BARER SOL J
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Lichtenstein Chen
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Crane Rosemary A
June 8, 2026 4:07 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Elstein Amir
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: LIEBERMAN GERALD M
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Nisen Perry
June 8, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Satchi-Fainaro Ronit
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Zaks Tal Zvi
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: MIGNONE ROBERTO
June 8, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 05 Filed by: Francis Richard D
June 8, 2026 4:01 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Francis Richard D
June 5, 2026 4:00 PM - SEC Filing
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's
June 5, 2026 11:30 AM - Globe NewsWire
Form 4 TEVA PHARMACEUTICAL INDU For: Jun 03 Filed by: Shields Matthew
June 4, 2026 4:01 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Shields Matthew
June 3, 2026 4:00 PM - SEC Filing
Form 8-K Immuneering Corp For: Jun 01
June 1, 2026 4:52 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Zaks Tal Zvi
June 1, 2026 4:17 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Satchi-Fainaro Ronit
June 1, 2026 4:15 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Nisen Perry
June 1, 2026 4:14 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: LIEBERMAN GERALD M
June 1, 2026 4:11 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Elstein Amir
June 1, 2026 4:10 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Crane Rosemary A
June 1, 2026 4:09 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: Lichtenstein Chen
June 1, 2026 4:08 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: BARER SOL J
June 1, 2026 4:05 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 28 Filed by: MIGNONE ROBERTO
June 1, 2026 4:04 PM - SEC Filing
Form 8-K TEVA PHARMACEUTICAL INDU For: May 28
May 28, 2026 4:50 PM - SEC Filing
Immuneering reports 17.3-month survival in pancreatic cancer trial
May 21, 2026 5:02 PM - StreetInsider
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026 5:00 PM - Globe NewsWire
EMA accepts Teva application for long-acting olanzapine schizophrenia drug
May 21, 2026 1:24 PM - StreetInsider
Medincell: The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable for the Treatment of Schizophrenia in Adults
May 21, 2026 1:24 PM - BizWire
Form 4 TEVA PHARMACEUTICAL INDU For: May 14 Filed by: Lippman Evan
May 18, 2026 4:03 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 14 Filed by: Kalif Eliyahu Sharon
May 18, 2026 4:01 PM - SEC Filing
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
May 18, 2026 8:30 AM - Globe NewsWire
Teva study reveals diagnostic gap in tardive dyskinesia among young adults
May 18, 2026 8:02 AM - StreetInsider
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 18, 2026 8:01 AM - Globe NewsWire
Form 10-Q Immuneering Corp For: Mar 31
May 15, 2026 7:52 AM - SEC Filing
Form 8-K Immuneering Corp For: May 15
May 15, 2026 7:44 AM - SEC Filing
Immuneering reports Q1 2026 financial results and clinical updates
May 15, 2026 7:35 AM - StreetInsider
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
May 15, 2026 7:35 AM - Globe NewsWire
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Lippman Evan
May 14, 2026 4:03 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Kalif Eliyahu Sharon
May 14, 2026 4:00 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 06 Filed by: Weiss Amir
May 7, 2026 4:04 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 05 Filed by: Daniell Richard
May 7, 2026 4:02 PM - SEC Filing
FDA greenlights continued generic access for Micardis
May 6, 2026 8:58 AM - StreetInsider
Teva Pharma (TEVA) PT Raised to $40 at Barclays
May 6, 2026 7:04 AM - StreetInsider
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Daniell Richard
May 5, 2026 4:00 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: May 01 Filed by: Sabag Mark
May 4, 2026 4:02 PM - SEC Filing
Form 4 TEVA PHARMACEUTICAL INDU For: Apr 30 Filed by: Fox Christine
May 4, 2026 4:01 PM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Sabag Mark
May 4, 2026 8:13 AM - SEC Filing
Form 144 TEVA PHARMACEUTICAL INDU Filed by: Fox Christine
April 30, 2026 4:41 PM - SEC Filing
Teva Pharma (TEVA) PT Raised to $42 at Piper Sandler
April 30, 2026 9:19 AM - StreetInsider
Teva Pharma (TEVA) PT Raised to $40 at JPMorgan
April 30, 2026 9:14 AM - StreetInsider
Teva Pharma (TEVA) PT Raised to $42 at UBS
April 30, 2026 6:25 AM - StreetInsider
Teva Pharma (TEVA) PT Lowered to $40 at BofA Securities
April 30, 2026 4:35 AM - StreetInsider
Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31
April 29, 2026 4:09 PM - SEC Filing
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
April 29, 2026 3:23 PM - StreetInsider
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
April 29, 2026 3:23 PM - StreetInsider
Medincell - UZEDY®: Q1 2026 Net Sales Reached $63M, Up 62% Year‑on‑Year
April 29, 2026 7:39 AM - BizWire
Teva Pharma (TEVA) Tops Q1 EPS by 5c; updates guidance
April 29, 2026 7:04 AM - StreetInsider
Form 8-K TEVA PHARMACEUTICAL INDU For: Apr 29
April 29, 2026 7:00 AM - SEC Filing
Teva to acquire Emalex Biosciences for $700 million upfront
April 29, 2026 6:30 AM - StreetInsider
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026 6:30 AM - Globe NewsWire
Full Article List
